India OKs Cadila's locally made diabetes drug Lipaglyn

06/6/2013 | Wall Street Journal, The

Regulators in India have approved Cadila Healthcare's diabetes drug Lipaglyn, making the company the first domestic drugmaker to be allowed to sell a treatment developed locally. Cadila plans to release the drug in India in the fourth quarter and to ask for FDA to conduct clinical trials, Chairman Pankaj Patel said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL